Compare PHVS & CUBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHVS | CUBI |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | Switzerland | United States |
| Employees | N/A | 869 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2020 | N/A |
| Metric | PHVS | CUBI |
|---|---|---|
| Price | $34.95 | $78.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $41.82 | ★ $85.00 |
| AVG Volume (30 Days) | ★ 566.0K | 323.7K |
| Earning Date | 05-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.95 |
| Revenue Next Year | N/A | $9.50 |
| P/E Ratio | ★ N/A | $11.78 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.12 | $59.34 |
| 52 Week High | $36.60 | $82.56 |
| Indicator | PHVS | CUBI |
|---|---|---|
| Relative Strength Index (RSI) | 57.18 | 53.99 |
| Support Level | $24.73 | $71.61 |
| Resistance Level | $36.60 | $79.19 |
| Average True Range (ATR) | 1.64 | 1.87 |
| MACD | -0.14 | -0.02 |
| Stochastic Oscillator | 54.17 | 52.23 |
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Customers Bancorp Inc is a bank holding company conducting banking activities through its wholly owned subsidiary, Customers Bank. The Bank provides commercial and consumer customers the stability of a regulated financial institution supported by risk management. It serves commercial and corporate businesses nationwide, including healthcare, real estate, specialty finance, fund finance, technology and venture capital banking, mortgage finance and commercial equipment financing, and provides payments and treasury services. The Bank also serves consumers through its branch network, offering residential mortgages and personal loan and deposit products, including Banking-as-a-Service, with services delivered predominantly in Southeastern and Central Pennsylvania, New York, and other states.